-
Thus our data indicate that Sept9_i2 is a negative regulator of breast tumorigenesis. We propose that Sept9 tumorigenic properties depend on the balance between Sept9_i1 and Sept9_i2 expression levels.
-
The plasma levels of septin-9 and clusterin in ovarian cancer patients were abnormally elevated, which might be used as potential candidates of peripheral blood tumor biomarkers for early diagnosis of EOC and septin-9 might be related to distal metastases of EOC.
-
The primary aim of this study was to evaluate the diagnostic accuracy of a PCR-based assay for the analysis of SEPT9 promoter methylation in circulating cell-free DNA (mSEPT9) for diagnosing hepatocellular carcinoma.
-
Septin 9 regulates lipid droplet growth through binding to phosphatidylinositol-5-phosphate in Hepatitis C virus infected cells.Septin 9 regulates lipid droplets growth and perinuclear accumulation in a manner dependent on dynamic microtubules.Septin 9 regulates Hepatitis C virus replication.
-
The SEPT9 assay exhibited satisfactory performance in colorectal cancer diagnosis and screening, while more evidence is needed for therapeutic effect monitoring and prognosis prediction.
-
Studies indicate that methylated Septin 9 ((m)SEPT9) can be consistently detected in plasma samples derived from whole blood samples collected with S-Monovette(R) K3E and BD Vacutainer (R) K2EDTA tubes stored at 2-8 degrees C for a maximum of 24 h and for samples collected in S-Monovette CPDA tubes stored at 18-25 degrees C for up to 48 h.
-
our study has validated a new SEPT9 assay and combined testing as an aid in cancer detection, providing a new approach for opportunistic CRC screening.
-
Study shows a stepwise increase of SEPT9 methylation from non-cancerous to cancerous tissue in colorectal adenocarcinoma.
-
Study found SHOX2 and SEPT9 frequently methylated in biliary tract cancers.
-
These results indicate that SEPT9_v2 promoter hypermethylation, which silences the expression of SEPT9_v2 mRNA, is observed in a significant proportion of breast tumors, and that methylated SEPT9_v2 may serve as a novel tumor marker for breast cancer.
-
The first evidence of an interaction between septins and a nonmitotic kinesin is provided and it is suggested that SEPT9 modulates the interactions of KIF17 with membrane cargo.
-
SEPT9 promoter methylation and MN frequency, both measured in peripheral blood, occur at an early stage compared to carcinoma development, indicating that the approach might be suitable to monitor CRC development.
-
KRAS mutations and SEPT9 promoter methylation were present in 34% (29/85) and in 82% (70/85) of primary tumor tissue samples.
-
SEPT9_i1 is expressed in high-grade prostate tumors suggesting it has a significant role in prostate tumorigenesis.
-
we demonstrate that SEPT9 negatively regulates EGFR degradation by preventing the association of the ubiquitin ligase Cbl with CIN85, resulting in reduced EGFR ubiquitylation
-
provide a full overview of the theoretical basis, development, validation, and clinical applications of the SEPT9 assay for both basic science researchers and clinical practitioners
-
Results show that in plasma samples, elevated methylated SEPT9 (mSEPT9) values were detected in colorectal cancer, but not in adenomas. Tissue levels of mSEPT9 alone are not sufficient to predict mSEPT9 levels in plasma.
-
Authors report here that the septins SEPT2, -9, -11, and probably -7 form fibrillar structures around the chlamydial inclusion.
-
Our results suggest that SEPT9 gene methylation is a valuable biomarker for screening CRC in the Chinese population
-
SEPT9 promoter methylation is detected in free circulating DNA of lung cancer patients
